Patients With Hepatocellular Carcinoma (HCC)
NCT07690683
Adenocarcinoma, Carcinoma
Roma, Italy
View Trial DetailsNCT Number: NCT06168357
Role of ADC value and DWI in abbreviated MRI compared to post-contrast CT in follow-up of HCC after TACE.
Trial opening soon.
Get Notified20 year–85 year
All sexes
Observational
Hepatocellular carcinoma (HCC) is the 5th most common cancer in the world and the most common in Egypt .
Trans-arterial chemoembolization (TACE) is the treatment recommended for unresectable HCC according to Barcelona clinic liver cancer staging and is widely used .
HCC is nourished only by the hepatic artery, so TACE causes ischemia and coagulative necrosis. However; viable neoplastic tissue residual may be seen after TACE. Assessment of post-TACE tumor response is important in determining treatment success and in guiding future therapy .
Many studies have assessed the diagnostic performance of multiphasic contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) in diagnosis of HCC with noted higher sensitivity of MRI compared to CT. CT or MRI are recommended for assessment of response after treatment as well .
Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) are functional MRI techniques that detect signal changes in tissues due to water proton motion. The intact membranes of viable tumor cells restrict water diffusion, whereas necrotic tumor cells with disrupted cell membranes exhibit increased water diffusion and which differentiate the biological activity of HCC
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Age between 20-year old and 85-year old
Exclusion criteria
Time frame: Baseline
correlation between tumor enhancement in arterial phase expressed as Hounsfield unit number and ADC value.
Contact information is provided by the study sponsor or research team.
Mostafa Ahmed Sayed, Lecturer
CONTACT
Nour Mokhles Farah, Resident doctor
CONTACT
Assiut University
Other
Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma Following Locoregional Treatment.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07690683
Adenocarcinoma, Carcinoma
Roma, Italy
View Trial DetailsNCT07704203
Adenocarcinoma, Carcinoma
View Trial DetailsNCT07691762
Adenocarcinoma, Carcinoma
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07685548
Adenocarcinoma, Carcinoma
View Trial Details